BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Nasonov EL. CORONAVIRUS DISEASE 2019 (COVID-19): A RHEUMATOLOGIST’S THOUGHTS. Naučno-praktičeskaâ revmatologiâ 2020;58:123-32. [DOI: 10.14412/1995-4484-2020-123-132] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 9.7] [Reference Citation Analysis]
Number Citing Articles
1 Sukmarova ZN, Ibragimova FM, Larina OM, Gromov AI, Nasonov EL. Pleurisy and pericarditis as a cause of atypical chest pain in patients with in early post-COVID-19 period. Medicinskaâ vizualizaciâ 2022;26:11-22. [DOI: 10.24835/1607-0763-1232] [Reference Citation Analysis]
2 Strizhakov LA, Babanov SA, Gulyaev SV, Azovskova TA, Lavrentieva NE, Baraeva RA. Reinfection of COVID-19 with multisystem manifestations in a medical worker: clinical observation. Med tr prom èkol 2022;62:680-685. [DOI: 10.31089/1026-9428-2022-62-10-680-685] [Reference Citation Analysis]
3 Vorobeva OV, Romanova IP. Pathological changes in organs in rheumatoid arthritis with secondary amyloidosis of the heart and kidneys on the background of COVID-19. Sovremennaâ revmatologiâ 2022;16:66-70. [DOI: 10.14412/1996-7012-2022-5-66-70] [Reference Citation Analysis]
4 Nasonov EL, Samsonov MY, Lila AM. Coronavirus Infection 2019 (COVID-19) and Autoimmunity. Her Russ Acad Sci 2022;92:398-403. [DOI: 10.1134/s1019331622040062] [Reference Citation Analysis]
5 Suprun MD, Beketova TV, Babak VV, Evsikova MD. Ocular Manifestations of COVID-19 in a Patient with ANCAAssociated Vasculitis Treated with Rituximab. A Case Report. Oftalʹmologiâ 2022;19:452-457. [DOI: 10.18008/1816-5095-2022-2-452-457] [Reference Citation Analysis]
6 Sukmarova ZN, Ibragimova FM, Afonina OV, Simonenko VB. Recurrent course of post-inflammatory cardiopathy: lessons from past epidemics. jour 2022;100:97-107. [DOI: 10.30629/0023-2149-2022-100-2-3-97-107] [Reference Citation Analysis]
7 Nasonov EL. Janus kinase inhibitors in immunoinflammatory rheumatic diseases. Terapevticheskii arkhiv 2022;94:605-609. [DOI: 10.26442/00403660.2022.05.201501] [Reference Citation Analysis]
8 Korolev MA, Letyagina EA, Sizikov AE, Bogoderova LA, Ubshaeva YB, Omelchenko VO, Akimova AA, Mullagaliev AA, Chumasova OA, Kurochkina YD. Immuno-inflammatory rheumatic diseases and COVID-19: analysis of clinical outcomes according to the data of the register of patients of the Novosibirsk region receiving therapy with genetically engineered biological drugs. Terapevticheskii arkhiv 2022;94:636-641. [DOI: 10.26442/00403660.2022.05.201502] [Reference Citation Analysis]
9 Nasonov EL, Korotaeva TV. Janus kinase inhibitors in immunoinflammatory diseases: 10 years of clinical practice in rheumatology. Naučno-praktičeskaâ revmatologiâ 2022;60:131-148. [DOI: 10.47360/1995-4484-2022-131-148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
10 Nasonov EL, Lila AM, Dubinina TV, Nikininskaya OA, Amirdjanova VN. Advances in rheumatology at the beginning of the 21st century. Naučno-praktičeskaâ revmatologiâ 2022;60:5-20. [DOI: 10.47360/1995-4484-2022-5-20] [Reference Citation Analysis]
11 Kulikov AN, Muravyeva NV, Belov BS. Safety of COVID-19 vaccines in patients with immunoinflammatory rheumatic diseases (preliminary data). Sovremennaâ revmatologiâ 2022;16:26-31. [DOI: 10.14412/1996-7012-2022-1-26-31] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
12 Nasonov EL, Feist E. Adult Still's disease: New horizons. Naučno-praktičeskaâ revmatologiâ 2021;59:645-665. [DOI: 10.47360/1995-4484-2021-643-663] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
13 Litvinova MA, Muravyeva NV, Belov BS. COVID-19 Therapy: the Role of Antirheumatic Drugs. A&Ch 2021;66:83-89. [DOI: 10.37489/0235-2990-2021-66-7-8-83-89] [Reference Citation Analysis]
14 Nasonov EL, Avdeeva AS. B cell depletion in immune-mediated rheumatic diseases and coronavirus disease 2019 (COVID-19). Naučno-praktičeskaâ revmatologiâ 2021;59:384-393. [DOI: 10.47360/1995-4484-2021-384-393] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
15 Mazurov VI, Belyaeva IB, Sarantseva LE, Chudinov AL, Bashkinov RA, Trofimov EA, Smulskaya OA, Inamova OV, Petrova MS, Melnikov ES. Impact of a new coronavirus infection on the clinical course of immunoinflammatory rheumatic diseases. HERALD of North-Western State Medical University named after I I Mechnikov 2021;13:39-47. [DOI: 10.17816/mechnikov72269] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
16 Karateev AE, Amirdzhanova VN, Nasonov EL, Lila AM, Alekseeva LI, Pogozheva EY, Filatova ES, Nesterenko VA. “Post-COVID syndrome”: The focus is on musculoskeletal pain. Naučno-praktičeskaâ revmatologiâ 2021;59:255-262. [DOI: 10.47360/1995-4484-2021-255-262] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
17 Nasonov EL, Lila AM, Mazurov VI, Belov BS, Karateev AE, Dubinina TV, Nikitinskaya OA, Baranov AA, Abdulganieva DI, Moiseev SV, Zagrebneva AI. Coronavirus Disease 2019 (COVID-19) and Immune-mediated Rheumatic Diseases. Recommendations of the Association of Rheumatologists of Russia. Naučno-praktičeskaâ revmatologiâ 2021;59:239-254. [DOI: 10.47360/1995-4484-2021-239-254] [Cited by in Crossref: 21] [Cited by in F6Publishing: 24] [Article Influence: 10.5] [Reference Citation Analysis]
18 Nasonov EL. 2019 Coronavirus disease (COVID-19): contribution of rheumatology. Terapevticheskii arkhiv 2021;93. [DOI: 10.26442/00403660.2021.05.200799] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
19 Gordeev AV, Galushko EA, Savushkina NM. The role of the angiotensins in the pathogenesis of inflammatory joint disease. Terapevticheskii arkhiv 2021;93:635-9. [DOI: 10.26442/00403660.2021.05.200796] [Reference Citation Analysis]
20 Nasonov EL. Coronavirus disease 2019 (COVID-19) and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2021;59:5-30. [DOI: 10.47360/1995-4484-2021-5-30] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
21 Belov BS, Lila AM. COVID-19 and rheumatology: A year later. Naučno-praktičeskaâ revmatologiâ 2021;59:31-36. [DOI: 10.47360/1995-4484-2021-31-36] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
22 Adamyan L, Vechorko V, Konysheva O, Kharchenko E, Doroshenko D. Post-COVID-19 syndrome in Obstetrics and Reproductive Medicine. Probl reprod 2021;27:30. [DOI: 10.17116/repro20212706130] [Reference Citation Analysis]
23 Glybochko PV, Fomin VV, Moiseev SV, Avdeev SN, Yavorovskiy AG, Brovko MY, Umbetova KT, Aliev VA, Bulanova EL, Bondarenko IB, Volkova OS, Gaynitdinova VV, Gneusheva TY, Dubrovin KV, Kapustina VA, Kraeva VV, Merzhoeva ZM, Nuralieva GS, Nogtev PV, Panasyuk VV, Politov ME, Popov AM, Popova EN, Raspopina NA, Royuk VV, Sorokin YD, Trushenko NV, Khalikova EY, Tsareva NA, Chikina SY, Chichkova NV, Akulkina LA, Bulanov NM, Ermolova LA, Zykova AS, Kitbalyan AA, Moiseev AS, Potapov PP, Tao EA, Sholomova VI, Shchepalina AA, Yakovleva AA. [Risk factors for the early development of septic shock in patients with severe COVID-19]. Ter Arkh 2020;92:17-23. [PMID: 33720599 DOI: 10.26442/00403660.2020.11.000780] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
24 Balabanova RM. Rheumatic diseases and viral infection: is there an association? Sovremennaâ revmatologiâ 2020;14:98-102. [DOI: 10.14412/1996-7012-2020-4-98-102] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Kaleda MI, Nikishina IP, Fedorov ES, Nasonov EL. Coronavirus Desease 2019 (COVID-19) in Children: Lessons from Pediatric Rheumatology. Naučno-praktičeskaâ revmatologiâ 2020;58:469-79. [DOI: 10.47360/1995-4484-2020-469-479] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
26 Nasonov EL. Coronavirus disease-2019 (COVID-19): value of IL-6 inhibitors. Pulʹmonologiâ (Mosk ) 2020;30:629-44. [DOI: 10.18093/0869-0189-2020-30-5-629-644] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
27 Baimukhamedov C. Elderly-onset rheumatoid arthritis: an outlook from a practicing rheumatologist. Naučno-praktičeskaâ revmatologiâ 2020;58:447-50. [DOI: 10.47360/1995-4484-2020-447-450] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
28 Nasonov EL, Beketova TV, Reshetnyak TM, Lila AM, Ananieva LP, Lisitsyna TA, Soloviev SK. Coronavirus disease 2019 (COVID-19) and immune-mediated inflammatory rheumatic diseases: at the crossroads of thromboinflammation and autoimmunity. Naučno-praktičeskaâ revmatologiâ 2020;58:353-67. [DOI: 10.47360/1995-4484-2020-353-367] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
29 Belov BS, Muravyeva NM, Tarasova GM. COVID-19 and Rheumatology: so far, so close. Medicinskij sovet 2020. [DOI: 10.21518/2079-701x-2020-8-135-143] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
30 Nasonov EL. IMMUNOPATHOLOGY AND IMMUNOPHARMACOTHERAPY OF CORONAVIRUS DISEASE 2019 (COVID-19): FOCUS ON INTERLEUKIN 6. Naučno-praktičeskaâ revmatologiâ 2020;58:245-61. [DOI: 10.14412/1995-4484-2020-245-261] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 3.3] [Reference Citation Analysis]
31 Nasonov EL, Lila AM. BARICITINIB: NEW PHARMACOTHERAPY OPTIONS FOR RHEUMATOID ARTHRITIS AND OTHER IMMUNE-MEDIATED INFLAMMATORY RHEUMATIC DISEASES. Naučno-praktičeskaâ revmatologiâ 2020;58:304-16. [DOI: 10.14412/1995-4484-2020-304-316] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 3.3] [Reference Citation Analysis]